Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324415 · ClinicalTrials.gov registry record · Phase 2
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00324415 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 45 participants.
The verdict
NCT00324415, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cisplatin, fluorouracil, and cetuximab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin, fluorouracil, and cetuximab together with radiation therapy works in treating patients with HIV and stage I, stage II, or stage III anal cancer.
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- BIOLOGICAL cetuximab
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324415
The ClinicalTrials.gov registry entry for NCT00324415 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00324415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324415 about?
NCT00324415 is a clinical study titled "Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the abili...
What is the current status of trial NCT00324415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00324415?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), cetuximab (BIOLOGICAL), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00324415?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.